Premium
EFFECT OF FENOLDOPAM ON THE ALDOSTERONE RESPONSE TO METOCLOPRAMIDE IN MAN
Author(s) -
DUPONT A. G.,
VANDERNIEPEN P.,
VOLCKAERT A.,
SMITZ J.,
VANSTEIRTEGHEM A. C.,
SIX R. O.
Publication year - 1986
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1986.tb00763.x
Subject(s) - metoclopramide , endocrinology , aldosterone , medicine , fenoldopam , receptor , agonist , vomiting
The effect of fenoldopam, a selective DA 1 ‐agonist, on the plasma aldosterone response to metoclopramide was studied in six hypertensive patients included in a multicentre double‐blind placebo controlled cross‐over study of the antihypertensive effects of fenoldopam. Fenoldopam significantly increased baseline plasma renin activity (PRA); baseline plasma aldosterone levels rose slightly. Baseline PRL and the PRL response to metoclopramide were not altered by fenoldopam. After metoclopramide, a significant increase of plasma aldosterone was observed during treatment with fenoldopam, as well as in the placeboperiod. The peak values were not significantly different and occurred at 15 min during both treatment periods. These results indicate that fenoldopam does not reduce metoclopramide‐induced aldosterone secretion and therefore suggest that the adrenal dopamine receptor is not identical to the vascular DA 1 receptor.